Hepatitis C Virus: The Rising Concerns and Growing Hopes, Report From the HCV Symposium, Fourth Tehran Hepatitis Congress, November 2011, Tehran, Iran

被引:6
作者
Alavian, Seyed Moayed [1 ]
Jabbari, Hossain [2 ,3 ]
Daryani, Nasser Ebrahimi [4 ,5 ]
Nami, Mohammad Torabi [6 ]
机构
[1] Baqiyatallah Univ Med Sci, Baqiyatallah Res Ctr Gastroenterol & Liver Dis, Tehran, Iran
[2] Univ Tehran Med Sci, Shariati Hosp, Dept Infect Dis, DDRI, Tehran, Iran
[3] Univ Dept Dermatol, Vienna Gen Hosp AKH, Dept Clin Immunol Allergy & Infect Dis, Vienna, Austria
[4] Univ Tehran Med Sci, Dept Gastroenterol, Tehran, Iran
[5] Univ Tehran Med Sci, Dept Hepatol, Tehran, Iran
[6] Shahid Beheshti Med Univ, Inst Cognit Sci Studies, Dept Neurosci, Tehran, Iran
关键词
Hepatitis C; Congresses; Iran; SUSTAINED VIROLOGICAL RESPONSE; ALPHA-2A PLUS RIBAVIRIN; HIV-INFECTED PATIENTS; PEGINTERFERON ALPHA-2A; UNITED-STATES; INTERFERON-ALPHA-2B; ADHERENCE; THERAPY; TRIAL;
D O I
10.5812/hepatmon.6679
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The rising concerns for future health burden of hepatitis C virus (HCV) in global scale has continuously encouraged preventing measures particularly public awareness programs. There is an increasing necessity for allocating HCV awareness issues in public scope, especially for high risk populations and patients. Proper knowledge of health care professionals and treating physicians and their attitude with regard to hepatitis C management is also crucial. Achieving this can be a constructive step forward in controlling and hopefully eradicating hepatitis C virus in our community. Having a clear scientific grasp on treatment options and protocols, the concept of "CURE" achievement in hepatitis C and the future hopes in enhancing virological response with the coming direct antiviral agents can significantly add to the current practices of treating hepatitis C. This scientific report paper outlines the insights communicated at the HCV symposium during the 4th Tehran Hepatitis Congress, November 2011, Tehran, Iran. Copyright (c) 2012 Kowsar Corp. All rights reserved.
引用
收藏
页码:423 / 429
页数:7
相关论文
共 29 条
[1]  
Alavian SM, 2009, HEPAT MON, V9, P211
[2]   Epidemiology and risk factors of HCV infection among hemodialysis patients in countries of the Eastern Mediterranean Regional Office of WHO (EMRO): A quantitative review of literature [J].
Alavian S.-M. ;
Tabatabaei S.-V. ;
Mahboobi N. .
Journal of Public Health, 2011, 19 (2) :191-203
[3]   The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States [J].
Armstrong, GL ;
Alter, MJ ;
McQuillan, GM ;
Margolis, HS .
HEPATOLOGY, 2000, 31 (03) :777-782
[4]   Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection [J].
Bacon, Bruce R. ;
Gordon, Stuart C. ;
Lawitz, Eric ;
Marcellin, Patrick ;
Vierling, John M. ;
Zeuzem, Stefan ;
Poordad, Fred ;
Goodman, Zachary D. ;
Sings, Heather L. ;
Poordad, Fred ;
Goodman, Zachary D. ;
Sings, Heather L. ;
Boparai, Navdeep ;
Burroughs, Margaret ;
Brass, Clifford A. ;
Albrecht, Janice K. ;
Esteban, Rafael .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (13) :1207-1217
[5]   Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients -: A randomized controlled trial [J].
Carrat, F ;
Bani-Sadr, F ;
Pol, S ;
Rosenthal, E ;
Lunel-Fabiani, F ;
Benzekri, A ;
Morand, P ;
Goujard, C ;
Pialoux, G ;
Piroth, L ;
Salmon-Céron, D ;
Degott, C ;
Cacoub, P ;
Perronne, C .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (23) :2839-2848
[6]  
Craxì A, 2011, J HEPATOL, V55, P245, DOI 10.1016/j.jhep.2011.02.023
[7]  
Environmental SCDoHa, 2007, ENV SCDOHA VIR HEP
[8]  
Faster G, 2008, ANTIVIR THER, V13, P3
[9]   Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. [J].
Fried, MW ;
Shiffman, ML ;
Reddy, KR ;
Smith, C ;
Marinos, G ;
Goncales, FL ;
Haussinger, D ;
Diago, M ;
Carosi, G ;
Dhumeaux, D ;
Craxi, A ;
Lin, A ;
Hoffman, J ;
Yu, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :975-982
[10]  
Friedman Robert M, 2010, Hepat Res Treat, V2010, P323926, DOI 10.1155/2010/323926